Association of high PDPN expression with pulmonary metastasis of osteosarcoma and patient prognosis

Wang,Xincheng; Li,Wei; Bi,Jiaqi; Wang,Jia; Ni,Linying; Shi,Qingtao; Meng,Qinggang

doi:10.3892/ol.2019.11053

Association of high PDPN expression with pulmonary metastasis of osteosarcoma and patient prognosis

Authors:
- Xincheng Wang
- Wei Li
- Jiaqi Bi
- Jia Wang
- Linying Ni
- Qingtao Shi
- Qinggang Meng
View Affiliations

Affiliations: Department of Orthopedics, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150010, P.R. China, Department of Orthopedics, The First Hospital of Harbin City, Harbin, Heilongjiang 150010, P.R. China, Department of Hepatobiliary Surgery, The Affiliated Cancer Hospital of Harbin Medical University, Harbin, Heilongjiang 150081, P.R. China, Department of Orthopedics, The Affiliated Cancer Hospital of Harbin Medical University, Harbin, Heilongjiang 150081, P.R. China, Department of Pathology, The Affiliated Cancer Hospital of Harbin Medical University, Harbin, Heilongjiang 150081, P.R. China
Published online on: November 5, 2019 https://doi.org/10.3892/ol.2019.11053
Pages: 6323-6330
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Podoplanin (PDPN) is an important positive regulator of platelet aggregation and functions as a lymphatic endothelial marker. PDPN has been observed to be expressed in human tumor tissues and various cancer cell lines. In the present study, PDPN expression in patients with primary osteosarcoma was assessed at the mRNA and protein levels, and the associations between PDPN expression and pulmonary metastasis (PM) and prognosis were examined. Reverse transcription‑quantitative PCR (RT‑qPCR) analysis was used to detect the expression levels of PDPN in primary osteosarcoma tissues and paired normal bone tissues (n=20 pairs). In addition, immunohistochemical analysis of PDPN expression was performed in 168 paraffin‑embedded osteosarcoma tissue specimens and 23 matched normal tissues. The RT‑qPCR results revealed higher mRNA expression levels of PDPN in patients with PM compared with patients without PM. Further survival analyses identified Enneking stage and PM as two independent prognostic indicators. Finally, univariate analysis revealed that high PDPN protein expression was significantly associated with Enneking stage and PM in patients with osteosarcoma.

View Figures

View References

1	Biazzo A and De Paolis M: Multidisciplinary approach to osteosarcoma. Acta Orthop Belg. 82:690–698. 2016.PubMed/NCBI
2	Biermann JS, Chow W, Reed DR, Lucas D, Adkins DR, Agulnik M, Benjamin RS, Brigman B, Budd GT, Curry WT, et al: NCCN guidelines insights: Bone cancer, version 2.2017. J Natl Compr Canc Netw. 15:155–167. 2017. View Article : Google Scholar : PubMed/NCBI
3	Nataraj V, Batra A, Rastogi S, Khan SA, Sharma MC, Vishnubhatla S and Bakhshi S: Developing a prognostic model for patients with localized osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate: A single-center experience of 237 patients. J Surg Oncol. 112:662–668. 2015. View Article : Google Scholar : PubMed/NCBI
4	Boye K, Del Prever AB, Eriksson M, Saeter G, Tienghi A, Lindholm P, Fagioli F, Skjeldal S, Ferrari S and Hall KS: High-dose chemotherapy with stem cell rescue in the primary treatment of metastatic and pelvic osteosarcoma: Final results of the ISG/SSG II study. Pediatr Blood Cancer. 61:840–845. 2014. View Article : Google Scholar : PubMed/NCBI
5	Heaton TE, Hammond WJ, Farber BA, Pallos V, Meyers PA, Chou AJ, Price AP and LaQuaglia MP: A 20-year retrospective analysis of CT-based pre-operative identification of pulmonary metastases in patients with osteosarcoma: A single-center review. J Pediatr Surg. 52:115–119. 2017. View Article : Google Scholar : PubMed/NCBI
6	Oki H, Kaneko MK, Ogasawara S, Tsujimoto Y, Liu X, Sugawara M, Takakubo Y, Takagi M and Kato Y: Characterization of monoclonal antibody LpMab-7 recognizing Non-PLAG domain of podoplanin. Monoclon Antib Immunodiagn Immunother. 34:174–180. 2015. View Article : Google Scholar : PubMed/NCBI
7	Kunita A, Kashima TG, Ohazama A, Grigoriadis AE and Fukayama M: Podoplanin is regulated by AP-1 and promotes platelet aggregation and cell migration in osteosarcoma. Am J Pathol. 179:1041–1049. 2011. View Article : Google Scholar : PubMed/NCBI
8	Kato Y, Kaneko MK, Kuno A, Uchiyama N, Amano K, Chiba Y, Hasegawa Y, Hirabayashi J, Narimatsu H, Mishima K and Osawa M: Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation-stimulating domain. Biochem Biophys Res Commun. 349:1301–1307. 2006. View Article : Google Scholar : PubMed/NCBI
9	Miyata K, Takemoto A, Okumura S, Nishio M and Fujita N: Podoplanin enhances lung cancer cell growth in vivo by inducing platelet aggregation. Sci Rep. 7:40592017. View Article : Google Scholar : PubMed/NCBI
10	Takagi S, Sato S, Oh-hara T, Takami M, Koike S, Mishima Y, Hatake K and Fujita N: Platelets promote tumor growth and metastasis via direct interaction between Aggrus/podoplanin and CLEC-2. PLoS One. 8:e736092013. View Article : Google Scholar : PubMed/NCBI
11	Swain N, Kumar SV, Routray S, Pathak J and Patel S: Podoplanin-a novel marker in oral carcinogenesis. Tumour Biol. 35:8407–8413. 2014. View Article : Google Scholar : PubMed/NCBI
12	Yamaki E, Yajima T, Kosaka T, Mogi A, Tanaka S and Kuwano H: Podoplanin overexpression in human mesothelioma cell lines enhances the tumorigenic phenotype. Oncol Rep. 29:932–940. 2013. View Article : Google Scholar : PubMed/NCBI
13	Kaneko MK, Oki H, Ogasawara S, Takagi M and Kato Y: Anti-podoplanin monoclonal antibody LpMab-7 detects metastatic lesions of osteosarcoma. Monoclon Antib Immunodiagn Immunother. 34:154–161. 2015. View Article : Google Scholar : PubMed/NCBI
14	DePaolo CJ, Foster WS, Dabezies EJ and D'Ambrosia RD: A case report of malignant mesenchymoma with discussion of musculoskeletal tumor staging: The Enneking system. Orthopedics. 11:1263–1276. 1988.PubMed/NCBI
15	Jo VY and Doyle LA: Refinements in sarcoma classification in the current 2013 world health organization classification of tumours of soft tissue and bone. Surg Oncol Clin N Am. 25:621–643. 2016. View Article : Google Scholar : PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Grimer RJ, Aydin BK, Wafa H, Carter SR, Jeys L, Abudu A and Parry M: Very long-term outcomes after endoprosthetic replacement for malignant tumours of bone. Bone Joint J. 98-B:857–864. 2016. View Article : Google Scholar : PubMed/NCBI
18	Koirala P, Roth ME, Gill J, Chinai JM, Ewart MR, Piperdi S, Geller DS, Hoang BH, Fatakhova YV, Ghorpade M, et al: HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survival. Sci Rep. 6:311542016. View Article : Google Scholar : PubMed/NCBI
19	Puri A, Byregowda S, Gulia A, Crasto S and Chinaswamy G: A study of 853 high grade osteosarcomas from a single institution-Are outcomes in Indian patients different? J Surg Oncol. 117:299–306. 2018. View Article : Google Scholar : PubMed/NCBI
20	Angelini A, Ceci F, Castellucci P, Graziani T, Polverari G, Trovarelli G, Palmerini E, Ferrari S, Fanti S and Ruggieri P: The role of ¹⁸F-FDG PET/CT in the detection of osteosarcoma recurrence. Eur J Nucl Med Mol Imaging. 44:1712–1720. 2017. View Article : Google Scholar : PubMed/NCBI
21	Kadota K, Huang CL, Liu D, Nakashima N, Yokomise H, Ueno M and Haba R: The clinical significance of the tumor cell D2-40 immunoreactivity in non-small cell lung cancer. Lung Cancer. 70:88–93. 2010. View Article : Google Scholar : PubMed/NCBI
22	Yuan P, Temam S, El-Naggar A, Zhou X, Liu DD, Lee JJ and Mao L: Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer. 107:563–569. 2006. View Article : Google Scholar : PubMed/NCBI
23	Minardi D, d'Anzeo G, Lucarini G, Filosa A, Zizzi A, Simonetti O, Polito M Jr, Offidani AM, Di Primio R, Montironi R and Muzzonigro G: D2-40 immunoreactivity in penile squamous cell carcinoma: A marker of aggressiveness. Hum Pathol. 42:1596–1602. 2011. View Article : Google Scholar : PubMed/NCBI
24	Nakazawa Y, Takagi S, Sato S, Oh-hara T, Koike S, Takami M, Arai H and Fujita N: Prevention of hematogenous metastasis by neutralizing mice and its chimeric anti-Aggrus/podoplanin antibodies. Cancer Sci. 102:2051–2057. 2011. View Article : Google Scholar : PubMed/NCBI
25	Martin-Villar E, Megias D, Castel S, Yurrita MM, Vilaró S and Quintanilla M: Podoplanin binds ERM proteins to activate RhoA and promote epithelial-mesenchymal transition. J Cell Sci. 119:4541–4553. 2006. View Article : Google Scholar : PubMed/NCBI
26	Wicki A, Lehembre F, Wick N, Hantusch B, Kerjaschki D and Christofori G: Tumor invasion in the absence of epithelial-mesenchymal transition: Podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell. 9:261–272. 2006. View Article : Google Scholar : PubMed/NCBI
27	Kunita A, Kashima TG, Morishita Y, Fukayama M, Kato Y, Tsuruo T and Fujita N: The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis. Am J Pathol. 170:1337–1347. 2007. View Article : Google Scholar : PubMed/NCBI
28	Suzuki-Inoue K, Kato Y, Inoue O, Kaneko MK, Mishima K, Yatomi Y, Yamazaki Y, Narimatsu H and Ozaki Y: Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. J Biol Chem. 282:25993–26001. 2007. View Article : Google Scholar : PubMed/NCBI
29	Nakazawa Y, Sato S, Naito M, Kato Y, Mishima K, Arai H, Tsuruo T and Fujita N: Tetraspanin family member CD9 inhibits Aggrus/podoplanin-induced platelet aggregation and suppresses pulmonary metastasis. Blood. 112:1730–1739. 2008. View Article : Google Scholar : PubMed/NCBI
30	Cueni LN, Hegyi I, Shin JW, Albinger-Hegyi A, Gruber S, Kunstfeld R, Moch H and Detmar M: Tumor lymphangiogenesis and metastasis to lymph nodes induced by cancer cell expression of podoplanin. Am J Pathol. 177:1004–1016. 2010. View Article : Google Scholar : PubMed/NCBI
31	Han J, Yong B, Luo C, Tan P, Peng T and Shen J: High serum alkaline phosphatase cooperating with MMP-9 predicts metastasis and poor prognosis in patients with primary osteosarcoma in Southern China. World J Surg Oncol. 10:372012. View Article : Google Scholar : PubMed/NCBI
32	Kim SH, Shin KH, Moon SH, Jang J, Kim HS, Suh JS and Yang WI: Reassessment of alkaline phosphatase as serum tumor marker with high specificity in osteosarcoma. Cancer Med. 6:1311–1322. 2017. View Article : Google Scholar : PubMed/NCBI
33	Marais LC, Bertie J, Rodseth R, Sartorius B and Ferreira N: Pre-treatment serum lactate dehydrogenase and alkaline phosphatase as predictors of metastases in extremity osteosarcoma. J Bone Oncol. 4:80–84. 2015. View Article : Google Scholar : PubMed/NCBI
34	Hao H, Chen L, Huang D, Ge J, Qiu Y and Hao L: Meta-analysis of alkaline phosphatase and prognosis for osteosarcoma. Eur J Cancer Care (Engl). 26:2017. View Article : Google Scholar
35	Nagano A, Ishimaru D, Nishimoto Y, Akiyama H and Kawai A: Primary bone sarcomas in patients over 40 years of age: A retrospective study using data from the bone tumor registry of Japan. J Orthop Sci. 22:749–754. 2017. View Article : Google Scholar : PubMed/NCBI
36	Lisenda L, Linda ZA, Snyman FPJ, Kyte RD and Lukhele M: Osteosarcoma patient outcomes at a South African tertiary hospital. S Afr Med J. 107:754–757. 2017. View Article : Google Scholar : PubMed/NCBI
37	Zhang B, Pang QJ, Zhang HJ and Yuan Y: Multivariate analysis for prognostic factors among 43 patients with osteosarcoma. Zhongguo Gu Shang. 24:982–986. 2011.(In Chinese). PubMed/NCBI